ThreatDown Launches Nexus Partner Program, Strengthening its Channel-First Commitment
11.11.2025 16:02:00 EET | Business Wire | Press release
ThreatDown, the corporate business unit of Malwarebytes, today announced the launch of the Nexus Partner Program, a comprehensive initiative that puts partners at the center by strengthening collaboration and creating new growth opportunities for its global network of partners. The program aligns incentives, simplifies enablement, and strengthens collaboration to ensure every reseller has the resources and support needed to deliver smarter, stronger security outcomes for customers.
“At ThreatDown, being channel-first means putting our partners at the center of everything we do,” says Kendra Krause, General Manager of ThreatDown. “The Nexus Partner Program reflects that belief – the program is built to equip partners with the tools they need to succeed in a rapidly evolving cybersecurity market. When our partners win, we win.”
Available globally, the program offers competitive discounts, revenue protection, marketing resources, and technical support. Unified under a single framework that prioritizes simplicity and sustainable growth, the Nexus Partner Program gives partners access to dedicated enablement teams focused on training, certification, and joint business planning to help them scale efficiently.
“ThreatDown is a strategic partner for us, providing comprehensive marketing and sales support throughout the customer lifecycle,” said Karen Greer, CEO of Secure Content Technologies. “They make doing business together easy – and together, we are a united front in providing quality protection and support.”
The launch of the Nexus Partner Program builds on a year of strong channel momentum for ThreatDown, including the appointment of Kendra Krause earlier this year as ThreatDown General Manager to lead the company’s next phase of channel-driven growth. Additionally, ThreatDown has advanced its channel-first mission through initiatives such as the self-service trial of the OneView management platform for MSPs, the Partner Sales and Technical Certification Program, and new strategic alliances with Bakotech, CMS Distribution, Onecom, SuperOps, and TeamViewer.
The Nexus Partner Program is currently available. Partners can learn more or join the program at https://www.threatdown.com/partner-program/partner-reseller/.
About ThreatDown
ThreatDown, the corporate business unit of Malwarebytes, is a leader in endpoint security simplicity. Fueled by world-class threat research, proprietary AI engines, and a legacy of eliminating threats others miss, ThreatDown is recognized by MRG Effitas, AVLab Cybersecurity Foundation, and G2 as a leader in threat detection and response. Our powerful, efficient, and easy-to-use solutions protect people, devices, and data – within minutes. The company is headquartered in California and has offices globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251111541593/en/
Contacts
ThreatDown Media Contact:
Julianne Cavanaugh, Public Relations
press@threatdown.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom